In a trading update ahead of its results, the AIM-listed provider of radiation detection equipment said it expected its underlying earnings (EBITDA) to break even, in line with market expectations, as it saw a growth in sales through executing both previously-signed agreements as well as new high-value contract wins during the year.
The group added that its products continue to gain traction in all its business segments from the increasing adoption of CZT-based technology, expecting to see further growth in the new financial year along with new customer wins.
The update follows a £1.4mln contract win for the company last week when it secured a three-year project by the UK’s innovation agency, Innovate UK to deliver a molecular breast imaging device.
The group will release its full-year results in July 2018.
In mid-morning trading Tuesday, Kromek shares were up 4.7% at 22.2p
--Adds share price--